View:
Download DOC
Download PDF
SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 		 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Gedra Ted S
(Last) (First) (Middle)
C/O 9341 COURTLAND DRIVE NE
(Street)
ROCKFORD MI 49351
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/02/2015 		3. Issuer Name and Ticker or Trading Symbol
WOLVERINE WORLD WIDE INC /DE/ [ WWW ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President, Heritage Group
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock(1) 252,739 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) (2) 02/06/2017 Common Stock 23,600 15.13 D
Stock Option (Right to Buy) (3) 02/05/2018 Common Stock 32,000 12.53 D
Stock Option (Right to Buy) (4) 02/09/2019 Common Stock 42,000 8.56 D
Stock Option (Right to Buy) (5) 02/10/2020 Common Stock 30,400 12.5 D
Stock Option (Right to Buy) (6) 02/08/2021 Common Stock 20,800 18.25 D
Stock Option (Right to Buy) (7) 02/07/2022 Common Stock 22,400 19.92 D
Stock Option (Right to Buy) (8) 02/05/2023 Common Stock 25,240 21.48 D
Stock Option (Right to Buy) (9) 02/10/2024 Common Stock 22,123 27.13 D
Explanation of Responses:
1. The number of shares reported includes 16,796 restricted shares of common stock granted to the reporting person on February 11, 2014, under the Company's Stock Incentive Plan of 2013. Subject to the Company's achievement of specified performance criteria in accordance with the terms of the grant, restrictions on such shares will lapse in February 2017. In addition, the number of shares reported includes 18,492 and 20,584 restricted shares of common stock granted to the reporting person on February 8, 2012, and February 6, 2013, respectively, under the Company's Stock Incentive Plan of 2010. Subject to the Company's achievement of specified performance criteria in accordance with the terms of the grant, restrictions on 18,492 and 20,584 of such shares will lapse in February 2015 and February 2016, respectively. Any shares as to which restrictions do not lapse at such times will be forfeited.
2. This option became exercisable as to 7,867 shares on February 7, 2008, as to 7,867 shares on February 7, 2009, and as to 7,866 shares on February 7, 2010.
3. This option became exercisable as to 10,667 shares on February 6, 2009, as to 10,667 shares on February 6, 2010, and as to 10,666 shares on February 6, 2011.
4. This option became exercisable as to 14,000 shares on February 10, 2010, as to 14,000 shares on February 10, 2011, and as to 14,000 shares on February 10, 2012.
5. This option became exercisable as to 10,134 shares on February 10, 2011, as to 10,133 shares on February 10, 2012, and as to 10,133 shares on February 10, 2013.
6. This option became exercisable as to 6,934 shares on February 9, 2012, as to 6,933 shares on February 9, 2013, and as to 6,933 shares on February 9, 2014.
7. This option became exercisable as to 7,467 shares on February 8, 2013, and as to 7,466 shares on February 8, 2014, and becomes exercisable as to 7,467 shares on February 8, 2015.
8. This option became exercisable as to 8,414 shares on February 6, 2014, and becomes exercisable as to 8,413 shares on February 6, 2015, and as to 8,413 shares on February 6, 2016.
9. This option becomes exercisable as to 7,375 shares on February 10, 2015, as to 7,374 shares on February 10, 2016, and as to 7,374 shares on February 10, 2017.
Remarks:
/s/ Timothy E. Foley, by Power of Attorney 01/12/2015
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
LIMITED POWER OF ATTORNEY

		The undersigned, a director and/or officer of Wolverine World Wide, Inc., a
Delaware corporation ("Wolverine"), does hereby appoint BRENDAN M. GIBBONS and
TIMOTHY E. FOLEY, or any one or more of them, with full power of substitution,
his or her attorneys and agents to do any and all acts and things and to execute
and file any and all documents and instruments that such attorneys and agents,
or any of them, consider necessary or advisable to enable the undersigned (in
his or her individual capacity or in a fiduciary or other capacity) to comply
with the Securities Act of 1933, as amended (the "Securities Act"), and the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any
requirements of the Securities and Exchange Commission in respect thereof, in
connection with his or her intended sale of any security related to Wolverine
pursuant to Rule 144 issued under the Securities Act and the preparation,
execution and filing of any report or statement of beneficial ownership or
changes in beneficial ownership of securities of Wolverine that the undersigned
(in his or her individual capacity or in a fiduciary or other capacity) may be
required to file pursuant to Section 16(a) of the Exchange Act including,
without limitation, full power and authority to sign the undersigned's name, in
his or her individual capacity or in a fiduciary or other capacity, to any
report or statement on Form 3, 4, 5 or 144, or to any amendments or any
successor forms thereto, or any form or forms adopted by the Securities and
Exchange Commission in lieu thereof or in addition thereto, hereby ratifying and
confirming all that such attorneys and agents, or any of them, shall do or cause
to be done by virtue hereof.

		The undersigned agrees that the attorneys-in-fact act as legal counsel to
and/or officers of Wolverine in connection with the securities matters addressed
herein, and do not represent the undersigned in his or her personal capacity in
connection with such matters.  The undersigned agrees that the attorneys-in-fact
may rely entirely on information furnished orally or in writing by the
undersigned or his or her authorized representative(s) to such
attorneys-in-fact.  The undersigned also agrees to indemnify and hold harmless
Wolverine and the attorneys-in-fact against any losses, claims, damages or
liabilities (or actions in respect thereof) that arise out of or are based upon
any untrue statement or omission of necessary fact in the information provided
by the undersigned or his or her authorized representative(s) to the
attorneys-in-fact for purposes of executing, acknowledging, delivering or filing
any such forms, or any amendments or any successor forms thereto, or any form or
forms adopted by the Securities and Exchange Commission in lieu thereof or in
addition thereto.  The undersigned agrees to reimburse Wolverine and the
attorneys-in-fact for any legal or other expenses reasonably incurred in
connection with investigating or defending against any such loss, claim, damage,
liability or action.

		This authorization shall supersede all prior authorizations to act for the
undersigned with respect to securities of Wolverine in these matters, which
prior authorizations are hereby revoked, and shall survive the termination of
the undersigned's status as a director and/or officer of Wolverine and remain in
effect thereafter for so long as the undersigned (in his or her individual
capacity or in a fiduciary or other capacity) is subject to Rule 144 with
respect to securities of Wolverine or has any obligation under Section 16 of the
Exchange Act with respect to securities of Wolverine.

Date:  January 7, 2015

/s/ Ted S. Gedra
(Signature)

Ted S. Gedra
(Name)